Assessing Psychiatric Adverse Effects during Clinical Drug Development

Rudorfer, Matthew V.; Hillefors, Mi

doi:10.1007/bf03262382

Cited by 2 publications

(4 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several methodological challenges in studying psychiatric adverse effects during drug development. The absence of commonly accepted and available animal models of mental disorders and symptomatology makes it difficult to study these effects in preclinical phases (Rudorfer 2012). Pre-marketing clinical trials are also of a short-term nature and thus do not offer an opportunity to observe adverse effects that emerge after months or even years (Rudorfer 2012).…”

Section: Problems Of Identifying Adverse Psychiatric Effectsmentioning

confidence: 99%

“…The absence of commonly accepted and available animal models of mental disorders and symptomatology makes it difficult to study these effects in preclinical phases (Rudorfer 2012). Pre-marketing clinical trials are also of a short-term nature and thus do not offer an opportunity to observe adverse effects that emerge after months or even years (Rudorfer 2012). In the recent past, reports of increased risk of suicidal thoughts and behaviour during treatment with some newly developed drugs have provoked concern among consumers regarding drug safety (Meyer 2010).…”

Section: Problems Of Identifying Adverse Psychiatric Effectsmentioning

confidence: 99%

“…the anti-obesity drug rimonabant and the antitubercular drug iproniazid) or received warnings from regulatory agencies in recent years (e.g. the anti-smoking drug varenicline, anti-acne drug isotretinoin and anti-epileptic drugs) owing to their adverse psychiatric effects (Rudorfer 2012). However, intangible evidence of such a risk for many drugs (e.g.…”

Section: Problems Of Identifying Adverse Psychiatric Effectsmentioning

confidence: 99%

“…Almost two-thirds of all the drugs included in the Physicians’ Desk Reference () have potential psychiatric adverse effects. Further, with the advent of newer drug molecules and improved surveillance, the list of implicated medications is steadily increasing (Turjanski 2005; Rudorfer 2012). Mechanisms for the psychiatric effects of some drugs are well understood, but for others they are unexpected and only partially comprehended (Desai 2004; Turjanski 2005).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Adverse psychiatric effects of non-psychotropic medications

Gupta

Chadda

2016

BJPsych advances

View full text Add to dashboard Cite

SummaryPatients presenting to psychiatrists frequently have comorbid medical conditions for which they are receiving treatment. A range of medications used for treatment of these conditions can have adverse effects resembling psychiatric symptoms. This article presents the results of our review of the literature on psychiatric adverse effects of various non-psychotropic medications, and discusses the mechanisms of such effects, their assessment and management. Among the commonly prescribed drugs found to have psychiatric adverse effects are corticosteroids, anti-Parkinsonian drugs, anti-epileptics, antiretrovirals, antibiotics, anticancer drugs, analgesics, drugs targeting endocrine and cardiovascular disorders, immunosuppressants, skeletal muscle relaxants and bronchodilators. Some adverse effects are predictable and dose dependent, whereas others are rare and idiosyncratic, and psychiatrists need to be aware of them for accurate diagnosis and appropriate treatment.

show abstract

Section: Problems Of Identifying Adverse Psychiatric Effectsmentioning

confidence: 99%

Section: Problems Of Identifying Adverse Psychiatric Effectsmentioning

confidence: 99%

Section: Problems Of Identifying Adverse Psychiatric Effectsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Adverse psychiatric effects of non-psychotropic medications

Gupta

Chadda

2016

BJPsych advances

View full text Add to dashboard Cite

show abstract

Miscellany

2021

The Maudsley Prescribing Guidelines in Psychiatry

View full text Add to dashboard Cite

Adherence to medication demands collaboration and agreement between the patient and the prescriber. A meta‐analysis and systematic review of such psychodynamic interventions, which included studies in unmedicated patients, confirmed the superiority of treatment with antipsychotics. Poor adherence to medication is a major risk factor for worse outcomes including relapse in people with schizophrenia, bipolar disorder and depression. There is evidence from controlled trials in a number of disease areas supporting the potential of financial incentives to enhance medication adherence. It is increasingly recognised that non‐psychotropic medications can induce a wide range of psychiatric symptoms. Psychiatric side effects are poorly characterised in drug clinical trials, often only becoming apparent during post‐marketing surveillance. The 1983 Mental Health Act (MHA) as amended by the 2007 MHA is the legislation within England and Wales that provides the framework for detaining and treating people with mental disorder in hospital.

show abstract

Assessing Psychiatric Adverse Effects during Clinical Drug Development

Cited by 2 publications

References 129 publications

Adverse psychiatric effects of non-psychotropic medications

Adverse psychiatric effects of non-psychotropic medications

Miscellany

Contact Info

Product

Resources

About